Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m.

Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team

Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end.

Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period.

BBS is currently in the process of searching for a new in-house CFO. The appointment will be announced separately.

For more information, please contact:

Juliusz Rakowski, CEO
[phone]
[e-mail]

Certified Advisor:
Nordic Certified Adviser AB,
[phone],
[e-mail]

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi